RJA
SYNH

Raymond James & Associates’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

Raymond James & Associates’s Portfolio SYNH Stock Details SYNH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-41,569
Closed -$1.75M – 3971
2023
Q2 		$1.75M Sell
41,569
-53,332
-56% -$2.16M ﹤0.01% 2142
2023
Q1 		$3.38M Sell
94,901
-11,888
-11% -$431K ﹤0.01% 1732
2022
Q4 		$3.92M Sell
106,789
-30,200
-22% -$1.19M ﹤0.01% 1571
2022
Q3 		$6.46M Sell
136,989
-18,225
-12% -$1.18M 0.01% 1211
2022
Q2 		$11.1M Buy
155,214
+12,915
+9% +$944K 0.01% 923
2022
Q1 		$11.5M Sell
142,299
-44,639
-24% -$3.78M 0.01% 989
2021
Q4 		$19.2M Buy
186,938
+4,280
+2% +$411K 0.02% 765
2021
Q3 		$16M Buy
182,658
+35,362
+24% +$3.2M 0.01% 821
2021
Q2 		$13.2M Sell
147,296
-1,458
-1% -$123K 0.01% 919
2021
Q1 		$11.3M Buy
148,754
+8,860
+6% +$668K 0.01% 958
2020
Q4 		$9.53M Buy
139,894
+35,907
+35% +$2.24M 0.01% 981
2020
Q3 		$5.53M Buy
103,987
+4,543
+5% +$271K 0.01% 1166
2020
Q2 		$5.79M Buy
99,444
+29,205
+42% +$1.57M 0.01% 1098
2020
Q1 		$2.77M Sell
70,239
-28,045
-29% -$1.64M ﹤0.01% 1387
2019
Q4 		$5.84M Sell
98,284
-936
-0.9% -$50.3K 0.01% 1159
2019
Q3 		$5.28M Sell
99,220
-4,264
-4% -$219K 0.01% 1195
2019
Q2 		$5.29M Buy
103,484
+11,611
+13% +$541K 0.01% 1186
2019
Q1 		$4.75M Sell
91,873
-17,083
-16% -$828K 0.01% 1222
2018
Q4 		$4.29M Buy
108,956
+514
+0.5% +$23.9K 0.01% 1192
2018
Q3 		$5.59M Buy
108,442
+22,100
+26% +$1.08M 0.01% 1148
2018
Q2 		$4.05M Buy
86,342
+27,515
+47% +$1.14M 0.01% 1324
2018
Q1 		$2.09M Buy
58,827
+10,329
+21% +$405K ﹤0.01% 1674
2017
Q4 		$2.12M Buy
48,498
+1,360
+3% +$63.5K ﹤0.01% 1650
2017
Q3 		$2.46M Buy
47,138
+4,917
+12% +$274K ﹤0.01% 1503
2017
Q2 		$2.47M Buy
42,221
+928
+2% +$48.2K 0.01% 1431
2017
Q1 		$1.89M Buy
41,293
+1,947
+5% +$96.9K ﹤0.01% 1563
2016
Q4 		$2.07M Sell
39,346
-1,501
-4% -$72.7K 0.01% 1468
2016
Q3 		$1.82M Buy
+40,847
New +$1.77M 0.01% 1511

Other funds holding SYNH

Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Natixis Advisors
Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Nomura Asset Management
Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $8.81B AUM 22.47% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's SYNH Position: Q3 2023 in Review

Raymond James & Associates sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 41,569 shares — an estimated $1.75M sold.

Raymond James & Associates first reported a position in SYNH in Q3 2016 and held it in 28 quarters. The position peaked at $19.2M in Q4 2021. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.

  • Raymond James & Associates reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 41,569 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.75M.
  • Raymond James & Associates first reported a position in Syneos Health, Inc. Class A Common Stock in Q3 2016 and held it in 28 quarters.
  • Raymond James & Associates's Syneos Health, Inc. Class A Common Stock position peaked at $19.2M in Q4 2021.
  • 10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.